csirt@kutim:~/threat-intel/cve/CVE-2023-28436

Katalog CVE

CVSS 8.0 · High EPSS 0,46%

Kerentanan Improper Privilege Management pada tailscale. Skor CVSS 3.1 8.0 (High) menurut NVD.

Deskripsi (NVD)

Tailscale is software for using Wireguard and multi-factor authentication (MFA). A vulnerability identified in the implementation of Tailscale SSH starting in version 1.34.0 and prior to prior to 1.38.2 in FreeBSD allows commands to be run with a higher privilege group ID than that specified in Tailscale SSH access rules. A difference in the behavior of the FreeBSD `setgroups` system call from POSIX meant that the Tailscale client running on a FreeBSD-based operating system did not appropriately restrict groups on the host when using Tailscale SSH. When accessing a FreeBSD host over Tailscale SSH, the egid of the tailscaled process was used instead of that of the user specified in Tailscale SSH access rules. Tailscale SSH commands may have been run with a higher privilege group ID than that specified in Tailscale SSH access rules if they met all of the following criteria: the destination node was a FreeBSD device with Tailscale SSH enabled; Tailscale SSH access rules permitted access for non-root users; and a non-interactive SSH session was used. Affected users should upgrade to version 1.38.2 to remediate the issue.

Rincian

Terbit di NVD
23 Maret 2023
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
8.0 (High), sumber NVD
CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-269: Improper Privilege Management
EPSS (30 hari)
0,46% peluang dieksploitasi; lebih tinggi dari 38,4% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
tailscale tailscale Versi 1.34 hingga sebelum 1.38.2

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.